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Abstract
Sorafenib-incoporated nanoparticles were prepared using a block copolymer that is composed of dextran and poly
(DL-lactide-co-glycolide) [DexbLG] for antitumor drug delivery. Sorafenib-incorporated nanoparticles were prepared
by a nanoprecipitation-dialysis method. Sorafenib-incorporated DexbLG nanoparticles were uniformly distributed in
an aqueous solution regardless of the content of sorafenib. Transmission electron microscopy of the sorafenib-
incorporated DexbLG nanoparticles revealed a spherical shape with a diameter < 300 nm. Sorafenib-incorporated
DexbLG nanoparticles at a polymer/drug weight ratio of 40:5 showed a relatively uniform size and morphology.
Higher initial drug feeding was associated with increased drug content in nanoparticles and in nanoparticle size. A
drug release study revealed a decreased drug release rate with increasing drug content. In an in vitro anti-
proliferation assay using human cholangiocarcinoma cells, sorafenib-incorporated DexbLG nanoparticles showed a
similar antitumor activity as sorafenib. Sorafenib-incorporated DexbLG nanoparticles are promising candidates as
vehicles for antitumor drug targeting.
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Introduction
Nanoparticles have been extensively investigated as a
means of specifically targeting drugs to a desirable site of
action [1]. Notably, nanoparticles having a hydrophobic
inner core and hydrophilic outer shell have received great
attention due to their superior properties in drug delivery
[2-6]. They are regarded to be ideal vehicles for antitumor
drug delivery because their hydrophobic inner core is an
appropriate reservoir for hydrophobic anticancer drugs
and because their hydrophilic outer shell facilitates avoid-
ance of the reticuloendothelial system, long blood circula-
tion, and the improvement of enhanced permeation and
retention [EPR] effect in tumor tissue [6].
Cholangiocarcinoma [CC], a malignant tumor arising
from the biliary tract, has a high mortality rate. Even
though surgical resection is regarded as a curative
method, most of patients diagnosed with a latent CC
state are not considered for surgical resection [7].
Furthermore, conventional radiation or chemotherapeu-
tic treatment is known to have limited advantages [7].
Therefore, novel treatment option is required to enhance
therapeutic efficacy of CC.
Sorafenib inhibits tumor cell proliferation and vasculari-
zation by the activation of the receptor for tyrosine kinase
signaling in the Ras/Raf/Mek/Erk cascade pathway [8].
Sorafenib is an effective chemotherapeutic agent against
various tumor types including CC [9] and inhibits prolif-
eration, angiogenesis, and invasion of tumor cells [9,10].
However, poor aqueous solubility and undesirable side
effects limit the clinical application and local treatment of
sorafenib. These side effects might be overcome by use of
nanoparticles for tumor delivery and controlled release of
sorafenib [11,12].
In this study, we prepared sorafenib-incorporated
DexbLG nanoparticles as an antitumor drug delivery
system. The properties of sorafenib-incorporated
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shell structure, particle size, morphology, and drug
release rate. Antitumor activity of sorafenib-incorpo-
rated DexbLG nanoparticles was tested using human
cholangiocarcinoma [HuCC-T1] cells.
Experimental details
Materials
Dextran from Leuconostoc spp. (average molecular weight
[MW] approximately 6,000), hexamethylene diamine
[HMDA], N,N-dicylohexylcarbodiimide [DCC], and N-
hydroxysuccimide [NHS] were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Sorafenib was purchased
from LC Laboratories (Woburn, MA, USA). Spectra/
Por™ dialysis membranes (MW cutoff [MWCO] = 2,000
g/mol and 8,000 g/mol) were purchased from Spectrum
Labs (Rancho Dominguez, CA, USA). Poly(DL-lactic acid-
co-glycolic acid) (PLGA-5005, MW = 5,000 g/mol) were
purchased from Wako Pure Chemicals (Osaka, Japan).
Synthesis of DexbLG copolymer
DexbLG copolymer was synthesized as reported previously
[13]. Aminated dextran was prepared as follows. Dextran
(180 mg) dissolved in dimethylsulfoxide [DMSO] was
mixed with sodium cyanoborohydride and stirred for 24 h.
After that, 10 equivalents of HMDA were added and stir-
red for 24 h at room temperature. The resulting aminated
dextran was obtained by dialysis against deionized water
and was lyophilized. N-hydroxysuccimide PLGA [PLGA-
NHS] was prepared by reaction with DCC and NHS.
DexbLG copolymer was prepared by dissolving 120 mg of
aminated dextran and 100 mg of PLGA-NHS in DMSO
and undergoing reaction for 2 days. Reactants were dia-
lyzed to remove unreacted dextran (MWCO of dialysis
membrane = 8,000 g/mol), and the product was lyophi-
lized. The resulting white powder was dissolved in chloro-
form to remove unreacted PLGA. Yield of the final
product was about 89% (w/w).
Preparation of sorafenib-incorporated DexbLG
nanoparticles
The sorafenib-incorporated DexbLG nanoparticles were
prepared by the nanoprecipitation-dialysis method as fol-
lows. DexbLG copolymer dissolved in 3 ml of DMSO was
mixed with sorafenib in 2 ml of DMSO. This solution was
added dropwise to 15 ml of deionized water for over 10
min to form nanoparticles. The solvent was removed by
dialysis against deionized water for 1 day. Empty nanopar-
ticles of DexbLG copolymer were prepared by the same
procedure, omitting sorafenib. To evaluate the drug con-
tents and loading efficiency, 5 mg of sorafenib-incorpo-
rated nanoparticles were distributed into the mobile phase
(acetonitrile/methanol/1% acetic acid in a ratio of
35:38:27) and stirred overnight. Drug concentration was
determined with high-performance liquid chromatography
[HPLC]. The drug content (in percent) was calculated
using the following equations:
Drug content =
Drug weight in the nanoparticles
Weight of the nanoparticles
× 100
and
Loading efﬁciency =
Residual drug in the nanoparticles
Initial feeding amount of drugs
× 100.
Analysis of nanoparticles
The characterization of nanoparticles was performed in
DMSO-d6 or D2Ou s i n g5 0 0M H z
1H nuclear magnetic
resonance [NMR] spectroscopy (500 MHz superconduct-
ing FT-NMR spectrometer; Varian Unity-Inova 500; Agi-
lent Technologies, Foster City, CA, USA). The morphology
of nanoparticles was observed by transmission electron
microscopy [TEM] using a JEM-2000 FX II microscope
(JEOL, Tokyo, Japan). One drop of nanoparticle solution
containing phosphotungstic acid (0.05% w/w) was placed
onto a carbon film coated on a copper grid for TEM.
Observation was done at an accelerating voltage of 80 kV.
The particle size and zeta potential were measured by the
Nano-ZS apparatus (Malvern Instruments, Malvern, UK).
A sample solution prepared by dialysis was used to deter-
mine the particle size.
Drug release study in vitro
The release experiment was carried out in vitro. A sample
solution prepared by dialysis was used directly. This solu-
tion was introduced into the dialysis membrane. Next, the
dialysis membrane was placed in a 200-ml bottle with 100
ml of phosphate buffered saline [PBS] containing 1% (v/v)
Tween 80 [PBST]. This bottle was placed in a shaking
incubator with a stirring speed of 100 rpm at a tempera-
ture of 37°C. At specific times, the PBST was sampled for
analysis of drug concentration. After each sampling, the
entire volume of PBST was replaced with fresh PBST to
prevent drug saturation. The concentration of the released
sorafenib was determined by HPLC.
HPLC analysis
The Flexar HPLC system (PerkinElmer, Waltham, MA,
USA) was equipped with a Solvent Manager 5-CH degas-
ser, an autosampler, a quaternary LC pump, a column
oven, and a UV-visible detector. Chromatography was
p e r f o r m e do nag u a r dc o l u m n( S e c u r i t y G u a r d
® Guard
Cartridge Kit; Phenomenex, Torrance, CA, USA) and on
a C18 column (Brownlee C18
®,5μm, 150 × 4.6; Perki-
nElmer) at 37°C. Sorafenib was eluted isocratically with
mobile phase (acetonitrile/methanol/1% acetic acid at a
r a t i oo f3 5 : 3 8 : 2 7 )a taf l o wr a t eo f1m l / m i na n d
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Page 2 of 6monitored at 254 nm. The chromatograms were
recorded and integrated with the Chromera 2.1 system
software (PerkinElmer).
Cell cytotoxicity test in vitro
HuCC-T1 cells maintained in RPMI 1640 (10% fetal
bovine serum, 5% CO2 at 37°C) were used to evaluate the
antitumor activity of sorafenib-incorporated nanoparticles.
Viability of tumor cells was evaluated by a 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
[MTT]-based cell proliferation assay. HuCC-T1 cells were
seeded at a density of 2 × 10
3 cells/well in 96-well plates
with 100 μl of medium before addition of polymeric
micelles. Next, free sorafenib, sorafenib-incorporated poly-
meric micelles, or empty polymeric micelles were added to
96-well plates at 100 μl. Controls were treated with 0.1%
(v/v) of DMSO. Cells were incubated for 48 h, and cell via-
bility was then measured in triplicate using an established
MTT assay protocol.
Results and discussion
Characterization of sorafenib-incorporated DexbLG
nanoparticles
Dextran is an appropriate macromolecule for block copo-
lymerization because it has one reductive end. DexbLG
copolymer was synthesized by the coupling of aminated
dextran and PLGA as described previously (Figure 1b)
[13]. In the block copolymer, dextran acts as a hydrophilic
domain and PLGA acts as a biodegradable hydrophobic
domain.
1H NMR revealed the theoretical [MWT]a n d
experimental [MWE]M W so fD e x bLG copolymer as
10,100 and 9,580 g/mol, respectively, while the MW of
PLGA was 4,920 g/mol (Mw) and 4,780 g/mol (Mn) in gel
permeation chromatography (data not shown). Because
the DexbLG copolymer is amphiphilic, it may form core-
shell type nanoparticles in an aqueous environment
[2,5,13]. In this configuration, dextran comprises the
hydrophilic outer shell, while PLGA comprises the hydro-
phobic core that is the actual reservoir of sorafenib.
Sorafenib (Figure 1a) is a relatively novel class of
angiogenesis inhibitor, which was selected as an antican-
cer drug due to its poor aqueous solubility. Nanoparti-
cles are regarded as an ideal candidate for these kinds of
drugs because the abundant microvascular structure of
the tumor tissue is a useful target for nanoparticulate
drug delivery system via the EPR effect.
Nanoparticles of DexbLG copolymer were prepared by
nanoprecipitation-dialysis method [13]. Nanoprecipita-
tion-dialysis method was superior over direct dialysis in
minimizing particle size of nanoparticles (data not
shown) [14]. Empty nanoparticles of DexbLG had a sphe-
rical shape with a diameter < 100 nm (Figure 2a). As
summarized in Table 1, their average particle size was 46
nm. Sorafenib-loaded DexbLG nanoparticles were
increased in size, with their size being related to the
quantity of drug loaded (Figure 2b,d). Among them,
nanoparticles with a polymer/dry weight ratio of 40:2 and
40:5 showed a relatively uniform size distribution in con-
trast to 40:7 nanoparticles. Particle size analysis of sorafe-
nib-incorporated DexbLG nanoparticles also showed an
increased average particle size according to the contents
of drug in the nanoparticles (Table 1). Zeta potential was
not significantly changed according to drug incorpora-
tion. Drug contents were increased according to the feed-
ing amount of drug (Table 1). Drug loading efficiency
was lowest at 40:2, while 40:5 and 40:7 nanoparticles
showed a loading efficiency > 35%.
To investigate the core-shell structure of nanoparticles
and drug incorporation,
1H NMR was adapted to mea-
sure nanoparticles in DMSO-d6 or D2O( F i g u r e3 ) .
Figure 1 Chemical structure of sorafenib (a) and DexbLG copolymer (b).
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1HN M Rs p e c -
trum between 0.5 and 9.5 ppm (Figure 3a). When sora-
fenib-incorporated nanoparticles were reconstituted in
D2O, only dextran peaks between 2.5 and 5.0 ppm were
observed, while specific sorafenib and PLGA peaks at
1.45, 3.35, and 4.9 ppm disappeared (Figure 3c). How-
ever, all the peaks of sorafenib, dextran domain, and
PLGA domain were apparent when nanoparticles were
dissolved in DMSO (Figure 3b). These results indicated
that sorafenib was successfully entrapped into the PLGA
core of the nanoparticles and that the dextran domain
constituted the hydrophilic outer shell.
Sorafenib release study was performed in vitro. Sorafenib
release rate from 40:5 nanoparticles into PBST was signifi-
cantly low, with < 10% of the total incorporated drug
being released over 2 weeks (Figure 4). Therefore, PBST
was used to maintain a sink condition in subsequent
experiments. The sorafenib release rate changed according
to the drug contents; increased drug incorporation
produces slower release rates (Figure 4b). Notably, an
initial burst of release from 40:2 nanoparticles was
observed until 6 h, followed by a sustained release of sora-
fenib for 2 weeks. Unexpectedly, 40:5 and 40:7 nanoparti-
cles showed a very low drug release for 2 weeks. This
phenomenon might be due to the hydrophobic interaction
at higher drug contents in the core of nanoparticles [2,13].
At higher drug contents, the hydrophobic drug might
crystallize in the solid core of the nanoparticles, which
would markedly hinder drug released [2]. However, when
the absolute amount of released drug was compared, 40:2
and 40:5 nanoparticles showed an almost equal amount of
drug release until 96 h (Figure 4a).
In vitro cell cytotoxicity
Antitumor activity of sorafenib-incorporated DexbLG
nanoparticles was tested using HuCC-T1 cells. Sorafenib
itself showed a dose-dependent antiproliferative effect
against tumor cells that was almost the same as that
Figure 2 TEM images of sorafenib-incorporated nanoparticles. Polymer:drug empty nanoparticle (a), 40:2 (b), 40:5 (c), 40:7 (d) nanoparticles.
Table 1 Characterization of sorafenib-incorporated nanoparticles
Polymer/drug
(mg/mg)
Drug contents (%, w/w) Loading efficiency
(%, w/w)
Particle size
(nm)
Zeta potential
(mV)
Theoretical Experimental
40:0 - - - 46 ± 1.12 -36.4 ± 3.1
40:2 4.76 1.23 25.84 63 ± 0.58 -35.5 ± 2.2
40:5 11.11 4.36 39.24 133 ± 0.58 -36.0 ± 1.1
40:7 14.89 5.26 35.33 181 ± 1.15 -35.8 ± 0.9
Kim et al. Nanoscale Research Letters 2012, 7:91
http://www.nanoscalereslett.com/content/7/1/91
Page 4 of 6produced by sorafenib-incorporated DexbLG nanoparti-
cles, while empty DexbLG nanoparticles did not signifi-
cantly inhibit cell viability (Figure 5). These results
indicate that DexbLG copolymer has no significant cyto-
toxicity against tumor cells, and sorafenib-incorporated
DexbLG has at least similar antitumor activity in vitro.
Nanoparticles or nanomatrix was known to improve
bioavailability [11] and antitumor activity in vivo [12]
with a decreased hemolysis or myelosuppression effect.
Our results demonstrate that DexbLG nanoparticles are
appropriate vehicles for sorafenib transport and release
and that the nanoparticles are superior candidates for
antitumor drug delivery.
Figure 3 1H NMR spectra. Sorafenib in DMSO (a); SORA-NP, sorafenib-incorporated nanoparticles in DMSO (b); and SORA-NP in D2O( c). The
box shows typical peaks of sorafenib (a), and the arrow shows typical peaks of PLGA (b).
Figure 4 Sorafenib release from the DexbLG nanoparticles.
Time course of the absolute amount of released sorafenib (a) and
total percentage of released sorafenib from DexbLG nanoparticles
(b). Drug release experiment of 40:2 (filled circle), 40:5 (empty circle),
and 40:7 (inverted filled triangle) was performed with PBST, and 40:5
(PBS; empty triangle) was performed with PBS only.
Figure 5 Growth inhibition of HuCC-T1 cells by treatment of
sorafenib-incorporated DexbLG nanoparticles. Two thousand
cells were exposed to sorafenib, empty nanoparticles, and sorafenib-
incorporated nanoparticles for 48 h.
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In this study, we prepared sorafenib-incorporated nano-
particles by nanoprecipitation-dialysis method. Sorafe-
nib-incorporated DexbLG nanoparticles adopt a
spherical shape with a size < 300 nm. The higher the
initial drug feeding, the higher is the quality of incorpo-
rated sorafenib. The size of the nanoparticles was
increased according to the amount of sorafenib. Increas-
ing quantity of incorporated sorafenib decreases the
release rate of the drug. Sorafenib-incorporated DexbLG
nanoparticles have a similar antitumor activity against
tumor cells in vitro compared to sorafenib itself. The
collective results indicate the promise of sorafenib-
incorporated DexbLG nanoparticles as vehicles for anti-
tumor drug targeting.
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